Technical Analysis for 0JDK - Iovance Biotherapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 1.96% | |
| Gapped Down | Weakness | 1.96% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.88% | |
| NR7 | Range Contraction | -1.88% | |
| Narrow Range Bar | Range Contraction | -1.88% | |
| Wide Bands | Range Expansion | -1.88% | |
| Up 3 Days in a Row | Strength | -1.88% | |
| Oversold Stochastic | Weakness | -1.88% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 19 hours ago |
| Possible NR7 | about 19 hours ago |
| Up 1% | about 19 hours ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | 2 days ago |
| Fell Below Previous Day's Low | 2 days ago |
Get a Trading Sidekick!
Iovance Biotherapeutics Inc. Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Classification
Keywords: Biotechnology Cancer Melanoma Cancer Immunotherapy Immunotherapy Metastatic Non Small Cell Lung Cancer Treatment Of Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.31 |
| 52 Week Low | 3.2194 |
| Average Volume | 40,351 |
| 200-Day Moving Average | 8.23 |
| 50-Day Moving Average | 13.99 |
| 20-Day Moving Average | 12.62 |
| 10-Day Moving Average | 11.72 |
| Average True Range | 0.68 |
| RSI (14) | 40.83 |
| ADX | 23.67 |
| +DI | 18.67 |
| -DI | 31.95 |
| Chandelier Exit (Long, 3 ATRs) | 13.12 |
| Chandelier Exit (Short, 3 ATRs) | 13.09 |
| Upper Bollinger Bands | 14.72 |
| Lower Bollinger Band | 10.51 |
| Percent B (%b) | 0.29 |
| BandWidth | 33.42 |
| MACD Line | -0.64 |
| MACD Signal Line | -0.56 |
| MACD Histogram | -0.0724 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.22 | ||||
| Resistance 3 (R3) | 12.17 | 11.95 | 12.14 | ||
| Resistance 2 (R2) | 11.95 | 11.82 | 11.97 | 12.11 | |
| Resistance 1 (R1) | 11.84 | 11.74 | 11.89 | 11.89 | 12.08 |
| Pivot Point | 11.62 | 11.62 | 11.64 | 11.64 | 11.62 |
| Support 1 (S1) | 11.51 | 11.49 | 11.56 | 11.56 | 11.37 |
| Support 2 (S2) | 11.29 | 11.41 | 11.31 | 11.34 | |
| Support 3 (S3) | 11.18 | 11.29 | 11.31 | ||
| Support 4 (S4) | 11.23 |
